While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer!

Artificial intelligence (AI) is certainly in the news constantly; however, it’s been used in drug discovery for some time.

A new collaboration between artificial intelligence drug discovery company Insilico Medicine and University of Toronto biochemist and molecular geneticist Igor Stagljar will test AI-designed molecules against "undruggable" cancer targets. 

The research will test 15 to 20 undruggable targets - but are they undruggable? And how does AI work in the drug discovery process?

This week, we have a conversation with Kyle Tretina, Alliance Manager of AI Platforms at Insilico Medicine, on a wide range of subjects including drug discovery, undruggable targets, the collaboration with the University of Toronto, and more.

00:58-05:11 : About Insilico Medicine
05:11-06:09 : Why is AI in the news?
06:09-07:39 : Helping people through AI
07:39-09:10 : What is Insilico Medicine doing with AI?
09:10-10:15 : Does Insilico Medicine take drugs from idea to trials?
10:15-11:32 : How do your partnerships come about?
11:32-19:34 : How does drug development start with AI?
19:34-24:43 : Can AI address undruggable targets?
24:43-25:05 : What do you need to do after finding a potential drug?
25:05-27:57 : Can quantum computing aid drug development?
27:57-30:13 : How can AI help reduce costs and save time?
30:13-32:56 : What is your partnership with the University of Toronto?
32:56-36:24 : What is the timescale for introducing drugs from AI?
36:24-37:29 : What conditions are you working on?

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter